Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics Limited, now trading on the ASX under the ticker TYP, has raised $6.5 million to advance its clinical trials, including a novel IV-infused psilocin formulation aimed at enhancing psychedelic-assisted therapy. The company has reported promising results, including an over 80% reduction in binge eating episodes in a recent study, and has established clinical trial pathways for two core programs targeting a variety of medical conditions with high unmet treatment needs.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
